Intravitreal axitinib implant well tolerated, safe in nAMD

Posted on

Interim analyses found that an intravitreal axitinib implant (OTX-TKI) was safe and generally well-tolerated in patients with neovascular AMD (nAMD), according to a poster presentation at AAO 2020 Virtual. Minimal movement and consistent resorption were reported.

In this ongoing prospective phase 1 trial evaluating safety, no ocular or systemic serious adverse events were reported. In patients treated with a dose of 400-μg, the mean reduction in central subfield thickness (CSFT), was observed by 2 months and maintained up to 4.5 months. In patients treated with 200-μg and 400-μg no additional anti-VEGF therapy was needed for >9 and >3 months, respectively, to date. In patients treated with 200-μg, minimal OTX-TKI movement was observed.

Boyer DS, et al. Safety and Biological Activity of Intravitreal OTX-TKI Implant in nAMD: Phase 1 Study. Presented at: AAO 2020 Virtual.

Related Articles
Wearable collision warning device helps visually impaired individuals
Jul 22, 2021
Psoriasis linked with significantly higher risk of retinal diseases
Jul 20, 2021
Ranibizumab biosimilar has comparable efficacy, safety profile to reference product in patients with nAMD
Jul 19, 2021